AustralianSuper Pty Ltd Purchases Shares of 119,130 Hologic, Inc. $HOLX

AustralianSuper Pty Ltd purchased a new stake in Hologic, Inc. (NASDAQ:HOLX) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 119,130 shares of the medical equipment provider’s stock, valued at approximately $7,763,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Chung Wu Investment Group LLC acquired a new stake in Hologic in the second quarter valued at $26,000. Caitong International Asset Management Co. Ltd increased its position in shares of Hologic by 193.6% during the second quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 273 shares in the last quarter. Zions Bancorporation National Association UT acquired a new stake in shares of Hologic during the first quarter worth about $34,000. Cromwell Holdings LLC increased its position in shares of Hologic by 307.0% during the second quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider’s stock worth $38,000 after purchasing an additional 436 shares in the last quarter. Finally, Allworth Financial LP increased its position in shares of Hologic by 46.0% during the first quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider’s stock worth $40,000 after purchasing an additional 216 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Hologic news, Director Christiana Stamoulis sold 7,402 shares of Hologic stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $73.07, for a total value of $540,864.14. Following the sale, the director owned 47,336 shares of the company’s stock, valued at approximately $3,458,841.52. The trade was a 13.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Stephen P. Macmillan sold 138,358 shares of Hologic stock in a transaction that occurred on Monday, September 22nd. The shares were sold at an average price of $66.97, for a total value of $9,265,835.26. Following the completion of the sale, the chief executive officer directly owned 1,234,624 shares in the company, valued at $82,682,769.28. This represents a 10.08% decrease in their position. The disclosure for this sale can be found here. 1.88% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of analysts have recently commented on HOLX shares. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $78.00 target price on shares of Hologic in a research report on Wednesday, October 22nd. Raymond James Financial cut Hologic from a “moderate buy” rating to a “hold” rating in a research report on Wednesday, October 22nd. Weiss Ratings reiterated a “hold (c-)” rating on shares of Hologic in a research report on Wednesday, October 8th. Mizuho cut Hologic from an “outperform” rating to a “neutral” rating and lifted their target price for the stock from $70.00 to $78.00 in a research report on Thursday, October 23rd. Finally, Wall Street Zen lowered Hologic from a “buy” rating to a “hold” rating in a report on Wednesday, October 1st. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and thirteen have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $79.23.

Hologic Stock Performance

NASDAQ HOLX opened at $73.95 on Tuesday. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 52-week low of $51.90 and a 52-week high of $84.39. The business’s 50-day moving average price is $67.78 and its 200 day moving average price is $64.13. The firm has a market cap of $16.45 billion, a P/E ratio of 30.68, a P/E/G ratio of 2.54 and a beta of 0.63.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same quarter last year, the company posted $1.06 earnings per share. The business’s revenue was up 1.2% on a year-over-year basis. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. On average, equities research analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.